ReNeuron Group Plc Company Profile (LON:RENE)

About ReNeuron Group Plc (LON:RENE)

ReNeuron Group Plc logoReNeuron Group plc is a clinical-stage company. The Company, through its subsidiaries, is engaged in researching and developing cell-based therapies. The Company's products are allogeneic. Its CTX stem cell therapy is used for the treatment of patients left disabled by the effects of a stroke. Its human retinal progenitor cells (hRPC) stem cell candidate is used for the treatment of retinitis pigmentosa (RP). Its second CTX stem cell candidate is for the treatment of critical limb ischaemia. The Company's exosomes nanomedicine platform focuses on generating early pre-clinical data in cancer. Its ReNcell Products include ReNcellVM and ReNcellCX cell lines. It is engaged in Phase II clinical trial of CTX cells for stroke disability. It is engaged in Phase I clinical trial of CTX cells for Critical Limb Ischaemia. It is engaged in Phase I clinical trial of hRPC stem cell candidate. The Company has completed pre-clinical trials CTX-derived exosomes.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: LON:RENE
  • CUSIP: N/A
  • Web: www.reneuron.com/
Capitalization:
  • Market Cap: £53.01 million
  • Outstanding Shares: 3,164,618,000
Average Prices:
  • 50 Day Moving Avg: GBX 1.83
  • 200 Day Moving Avg: GBX 2.01
  • 52 Week Range: GBX 1.55 - GBX 3.68
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.000
Sales & Book Value:
  • Annual Revenue: $899,999.00
  • Price / Sales: 58.90
  • Book Value: GBX 0.02 per share
  • Price / Book: 0.99
Profitability:
  • EBIDTA: ($18,130,000.00)
  • Net Margins: -32,825.00%
  • Return on Equity: -27.66%
  • Return on Assets: -25.36%
Misc:
  • Average Volume: 3.01 million shs.
 

Frequently Asked Questions for ReNeuron Group Plc (LON:RENE)

What is ReNeuron Group Plc's stock symbol?

ReNeuron Group Plc trades on the London Stock Exchange (LON) under the ticker symbol "RENE."

Where is ReNeuron Group Plc's stock going? Where will ReNeuron Group Plc's stock price be in 2017?

2 brokerages have issued 12-month price targets for ReNeuron Group Plc's stock. Their forecasts range from GBX 9 to GBX 15. On average, they expect ReNeuron Group Plc's stock price to reach GBX 12 in the next year. View Analyst Ratings for ReNeuron Group Plc.

Who are some of ReNeuron Group Plc's key competitors?

Who are ReNeuron Group Plc's key executives?

ReNeuron Group Plc's management team includes the folowing people:

  • Olav Hellebo, Chief Executive Officer, Director
  • Michael Elliott Hunt, Chief Financial Officer, Executive Director, Company Secretary
  • John D. Sinden Ph.D., Chief Scientific Officer, Executive Director
  • Sharon Grimster, Vice President Development and General Manager, Wales
  • Randolph Corteling, Head of Research
  • Julian Howell, Chief Medical Officer
  • Shaun Stapleton, Head - Regulatory Affairs
  • John Edward Berriman, Non-Executive Chairman of the Board
  • Simon Christopher Cartmell, Non-Executive Director
  • Timothy Henry Corn, Non-Executive Director

How do I buy ReNeuron Group Plc stock?

Shares of ReNeuron Group Plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is ReNeuron Group Plc's stock price today?

One share of ReNeuron Group Plc stock can currently be purchased for approximately GBX 1.68.


MarketBeat Community Rating for ReNeuron Group Plc (LON RENE)
Community Ranking:  3.8 out of 5 (star star star)
Outperform Votes:  79 (Vote Outperform)
Underperform Votes:  25 (Vote Underperform)
Total Votes:  104
MarketBeat's community ratings are surveys of what our community members think about ReNeuron Group Plc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for ReNeuron Group Plc (LON:RENE) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: GBX 12

Analysts' Ratings History for ReNeuron Group Plc (LON:RENE)
Show:
DateFirmActionRatingPrice TargetDetails
6/29/2017N+1 SingerReiterated RatingBuyView Rating Details
4/4/2017Stifel NicolausReiterated RatingBuyGBX 15View Rating Details
(Data available from 9/19/2015 forward)

Earnings

Earnings History for ReNeuron Group Plc (LON:RENE)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for ReNeuron Group Plc (LON:RENE)
Current Year EPS Consensus Estimate: $-0.730 EPS

Dividends

Dividend History for ReNeuron Group Plc (LON:RENE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for ReNeuron Group Plc (LON:RENE)
Insider Trades by Quarter for ReNeuron Group Plc (LON:RENE)
Insider Trades by Quarter for ReNeuron Group Plc (LON:RENE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/7/2017Michael HuntInsiderBuy250,000GBX 3£7,500
2/17/2016Hunt,MichaelInsiderSell509,554GBX 3£15,286.62
2/12/2016Hunt,MichaelInsiderSell594,637GBX 3£17,839.11
2/11/2016Hunt,MichaelInsiderSell1,208,333GBX 3£36,249.99
2/5/2016Hunt,MichaelInsiderSell1,035,533GBX 3£31,065.99
2/2/2016Edward Berriman,JohnInsiderBuy318,476GBX 3£9,554.28
1/29/2015Olav HellebøInsiderBuy322,778GBX 3.10£10,006.12
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for ReNeuron Group Plc (LON:RENE)
Latest Headlines for ReNeuron Group Plc (LON:RENE)
Source:

Social

Social activity is not available for this stock.

Chart

ReNeuron Group Plc (RENE) Chart for Tuesday, September, 19, 2017

This page was last updated on 9/19/2017 by MarketBeat.com Staff